News

BioSpace22h
Apellis, Sobi See Potential ‘Best-in-Class’ Efficacy for Empaveli in Rare Kidney Diseases
Empaveli reduced proteinuria by 68% versus placebo in glomerulopathy and glomerulonephritis, an effect that was sustained ...
The Lancet2d
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial
aDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA bDivision of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA cDivision of ...